Navigation Links
WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
Date:1/16/2008

SHANGHAI, China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's leading provider of pharmaceutical R&D outsourcing services is proud to announce today that its Chairman and Chief Executive Officer Dr. Ge Li is named as one of the 2007 China Top 10 Influential Entrepreneurs selected by Entrepreneur China edition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The 2007 China Top 10 Influential Entrepreneurs selection, organized by Entrepreneur China edition, aims to honor Chinese entrepreneurs who have enabled enormous leaps for their enterprises and whose experiences have prompted profound changes in the Chinese society during the year of 2007. The selection of the winners is based on a comprehensive set of parameters to evaluate the entrepreneur's contribution to revenue growth, employment opportunities, industry impact, public influence and social recognition, capital market performance, wealth creation for employees, as well as social responsibilities. Seeking to exemplify China's most successful entrepreneurs and inspire the new generation to run their own businesses, the organizer selected China's ten most influential business luminaries from over 100 achieved entrepreneurs who brought their companies public in 2007.

Dr. Li has won the award because of his deep understanding of the global pharmaceutical R&D outsourcing market and the successful implementation of his visionary business model and strategy in China. "Under Dr. Li's leadership, WuXi PharmaTech is playing an increasingly important role in the global drug discovery and development industry. This eventually will positively impact China's pharmaceutical industry," according to Entrepreneur.

Founded in 2000, through seven years of rapid development, WuXi PharmaTech has gained trust and confidence from the world's leading pharmaceutical and biotechnology companies for its high quality drug R&D outsourcing services. In August 2007, WuXi PharmaTech went public as the first NYSE listed company in China's rapidly growing pharmaceutical R&D outsourcing industry.

"I am very honored to be included on this list and to see WuXi PharmaTech's success recognized by Entrepreneur," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Our modest success is attributable to the support and trust from our customers and our unwavering focus on quality. China's advantageous business environment and rapid economic growth have created many opportunities for entrepreneurs. I hope more people can realize their dreams and create value for their customers, employees and the society."

About Entrepreneur China Edition

Entrepreneur China edition is a monthly business magazine issued by International Data Group (IDG) and Zero2IPO Group. As China's sole licensed partner of Entrepreneur Media Inc., Entrepreneur China edition provides networks and guidelines to Chinese entrepreneurs by offering Chinese business owners with inspiration and information on marketing, management, technology, the latest trends and strategies.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies with a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services; and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Aflac Honored with Corporate Citizenship Award
11. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Eurofins announces the appointment of ... of Eurofins Scientific Inc. (ESI). Mr. Murray will ... professional and entrepreneurial experience in leading international business teams. As the ... testing market to uphold Eurofins, status as the global leader in ... , ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... In response to client demand KbioBox developed a sophisticated “3 click” gene dditing ... are accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
Breaking Biology Technology:
(Date:12/6/2016)... Ind. , Dec. 6, 2016  Zimmer Biomet Holdings, ... it has priced an offering of €500.0 million principal amount ... million principal amount of its 2.425% senior unsecured notes due ... expected to occur on December 13, 2016, subject to the satisfaction ... an annual basis. The ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):